04:34 PM EDT, 08/14/2025 (MT Newswires) -- Profound Medical ( PROF ) after trade Thursday said its second-quarter loss widened while revenue stayed consistent year-over-year.

The medical device company lost US$15.7 million, or US$0.52 per share, in the period, compared with a loss of US$6.9 million, or US$0.28, a year ago. FactSet expected a loss of US$0.37 per share.

Revenue stood at US$2.2 million, the same as the year-ago quarter. FactSet projected US$3.3 million.

The company said that US$1.6 million of the revenue was from recurring, non-capital revenue, comprising the sale of TULSA-PRO consumables, lease of capital equipment, and services related to extended warranties, and US$650,000 from the one-time sale of capital equipment.

"The second quarter was characterized by some unfortunate timing, as we experienced what we believe are short-term delays in completing a few TULSA-PRO capital sales," Chief Executive Arun Menawat said.

If those deals had been completed during the quarter, total revenue would have exceeded US$3 million, he said, adding that the company remains focused on reaching its full-year revenue growth target of around 70% to 75% in 2025.

Profound shares closed down $0.03 to $7.54 on the Toronto Stock Exchange.